Clinical Trials Directory

Trials / Completed

CompletedNCT03493386

Daprodustat Bioequivalence and Food Effect Study

A Single Centre, Single Dose, Open-label, Randomised, 2-way Crossover Study in Healthy Japanese Male Subjects to Evaluate the Bioequivalence of Daprodustat Tablets (2 mg Tablet vs. 4 mg Tablet) (Part 1) and the Food Effect on the Pharmacokinetics of Daprodustat (Part 2)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
64 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
Male
Age
20 Years – 55 Years
Healthy volunteers
Accepted

Summary

This is two-way crossover study to compare pharmacokinetic (PK) of daprodustat 2 milligram (mg) versus 4 mg tablets and food effect on the PK of daprodustat following single oral doses in healthy Japanese male subjects. This study will be conducted in two parts. Part 1 is the bioequivalence part in which subjects will receive single dose of 2 tablets of 2 mg daprodustat and single dose of 1 tablet of 4 mg daprodustat in crossover manner. Part 2 is Food effect part. In this part, subjects will receive single dose of 4 mg daprodustat tablet in fasting and fed state in a crossover manner. There will 5-day wash-out period between each intervention period. There will be approximately 52 subjects in Part 1 and 12 subjects in Part 2. The study will last for 6 weeks.

Conditions

Interventions

TypeNameDescription
DRUGDaprodustat 2 mg tabletDaprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
DRUGDaprodustat 4 mg tabletDaprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.

Timeline

Start date
2018-04-24
Primary completion
2018-06-09
Completion
2018-06-09
First posted
2018-04-10
Last updated
2020-07-08
Results posted
2019-08-06

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT03493386. Inclusion in this directory is not an endorsement.